Cat. No. | Product name | CAS No. |
DCL-046 |
Triptolide,14-deoxy-14-oxo
>98%,Standard References |
38647-11-9 |
DCS-054 |
Carnosic acid
>98%,Standard References |
3650-09-7 |
DC10976 |
E-7386
Featured
E-7386 (E7386) is a potent, orally active modulator of CBP/beta-catenin, disrupts the interaction and inhibits canonical Wnt signaling pathway /TCF reporter gene activity in LiCl-stimulated HEK-293 and MDA-MB-231 with IC50 of 55 and 73 nM, respectively. |
1799824-08-0 |
DC7414 |
FH535
Featured
FH535 is a compound that suppresses both Wnt/beta-catenin and peroxisome proliferator-activated receptor (PPAR) signaling. |
108409-83-2 |
DC3130 |
ICG-001
Featured
ICG-001 is a small-molecule antagonist of b-catenin/TCF-mediated transcription (IC50 = 3 uM) and specifically downregulates the expression of a subset of b-catenin/TCF-responsive genes. ICG-001 binds specifically to cyclic AMP response element-binding pro |
780757-88-2 |
DC10680 |
iCRT3
Featured
iCRT3 is an inhibitor of both Wnt and β-catenin-responsive transcription. |
901751-47-1 |
DC9952 |
IQ-1
Featured
IQ-1 has many functions such as decreasing Wnt-stimulated phosphorylation, maintaining the pluripotency of murine ESCs, preventing PP2A/Nkd interaction and so on. |
331001-62-8 |
DC10556 |
KY1220
Featured
KY1220 is a compound that destabilizes both β-catenin and Ras, via targeting the Wnt/β-catenin pathway; with an IC50 of 2.1 μM in HEK293 reporter cells. |
292168-79-7 |
DC9880 |
KYA1797K
Featured
KYA1797K is a highly potent and selective Wnt/β-catenin inhibitor with IC50 of 0.75 µM (TOPflash assay). |
1956356-56-1 |
DC12384 |
LF3
Featured
LF3 is a specific inhibitor of canonical Wnt signaling by disrupting the interaction between β-catenin and TCF4 with an IC50 less than 2 μM. |
664969-54-4 |
DC10409 |
PNU-74654
PNU-74654 is an inhibitor of Wnt/β-catenin pathway with an IC50 of 129.8 μM in NCI-H295 cell. |
113906-27-7 |
DC10888 |
SKL2001
Featured
SKL2001 is an agonist of the Wnt/β-catenin pathway, with anti-cancer activity. |
909089-13-0 |
DC10472 |
Toxoflavin (PKF118-310)
Featured
Toxoflavin is an inhibitor of survivin expression and antagonist of Tcf4/b-catenin signaling |
84-82-2 |
DC28730 |
N-Desmethylnefopam
N-Desmethylnefopam is the main metabolite of Nefopam. N-Desmethylnefopam is a centrally-acting but non-opioid analgesic agent, for the relief of moderate to severe pain. Nefopam targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo. |
46868-19-3 |
DC29001 |
CWP232228
Featured
CWP232228, a highly potent selective Wnt/β-catenin signaling inhibitor, antagonizes binding of β-catenin to T-cell factor (TCF) in the nucleus. CWP232228 suppresses tumor formation and metastasis without toxicity through the inhibition of the growth of breast and liver cancer stem cells (CSCs). |
1144044-02-9 |
DC40956 |
β-catenin-IN-2
Featured
β-catenin-IN-2 is a potent β-catenin inhibitor, compound H1B1, extracted from patent US20150374662A1. β-catenin-IN-2 can be used for the study of colorectal cancer. |
1458664-10-2 |
DC46190 |
PRI-724
Featured
PRI-724 (C-82 prodrug, ICG-001 analog) is a potent and specific inhibitor that disrupts the interaction of β-catenin and CBP. |
1422253-38-0 |
DC46310 |
Nefopam D3 hydrochloride
Nefopam D3 hydrochloride is the deuterium labeled Nefopam hydrochloride. Nefopam hydrochloride (Fenazoxine hydrochloride) is a centrally-acting but non-opioid analgesic drug, for the relief of moderate to severe pain. Nefopam hydrochloride targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo. |
1346603-30-2 |
DC46397 |
ZW4864 free base
ZW4864 (free base) is an orally active and selective β catenin/B-Cell lymphoma 9 protein−protein interaction (β catenin/BCL9 PPI) inhibitor. ZW4864 (free base) inhibits β catenin/BCL9 PPI with a Ki value of 0.76 μM and an IC50 value of 0.87 μM. |
2632259-92-6 |
DC46398 |
ZW4864
ZW4864 is an orally active and selective β catenin/B-Cell lymphoma 9 protein−protein interaction (β catenin/BCL9 PPI) inhibitor. ZW4864 inhibits β catenin/BCL9 PPI with a Ki value of 0.76 μM and an IC50 value of 0.87 μM. |
2632259-93-7 |
DC70375 |
E722-2648
Featured
E722-2648 (Compound C-1) is a novel specific and competitive small molecule β-catenin/BCL9 interaction inhibitor with ITC KD of 1.05 uM and IC50 of 9 uM, blocks oncogenic Wnt signaling and disrupts cholesterol homeostasis in colorectal cancer.E722-2648 (Compound C-1) inhibited β-catenin/BCL9 complexes at concentrations as low as 1 uM in BCL9-dependent CRC cell lines, Colo320 and HCT116.E722-2648 (Compound C-1) inhibited the expression of bona fide downstream Wnt/β-catenin target genes, AXIN2 and CD44, in the β-catenin/BCL9-dependent CRC cell lines.E722-2648 (Compound C-1) disrupted cholesterol homeostasis via increased cholesterol esterification and lipid droplet accumulation.E722-2648 (Compound C-1) demonstrated antitumorigenic activity in CRC cell lines and xenograft mouse models. |
931963-55-2 |
DC70427 |
GB1874
GB1874 is an inhibitor of the Wnt pathway that targets the β-catenin-TCF4 interaction.GB1874 affected the proliferation and stemness of Wnt-addicted colorectal cancer (CRC) cells in vitro.GB1874 inhibited the growth of CRC tumor xenografts in vivo. |
1011440-46-2 |